摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,4'-di(1H-imidazol-4-yl)biphenyl | 100146-16-5

中文名称
——
中文别名
——
英文名称
4,4'-di(1H-imidazol-4-yl)biphenyl
英文别名
1(3)H,1'(3')H-4,4'-biphenyl-4,4'-diyl-bis-imidazole;4,4'-Di--diphenyl;4,4'-(Biphenyl-4,4'-diyl)bis(1H-imidazole);5-[4-[4-(1H-imidazol-5-yl)phenyl]phenyl]-1H-imidazole
4,4'-di(1H-imidazol-4-yl)biphenyl化学式
CAS
100146-16-5
化学式
C18H14N4
mdl
——
分子量
286.336
InChiKey
JHUZGJNYFDJSGF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    728.7±45.0 °C(Predicted)
  • 密度:
    1.253±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    22
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    57.4
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    4,4'-di(1H-imidazol-4-yl)biphenylcobalt(II) nitrate hexahydrate檀香(SANTALUMALBUM)提取物N,N-二甲基甲酰胺乙腈 为溶剂, 反应 72.0h, 以21%的产率得到[Co2(HL)2(BPDA)]
    参考文献:
    名称:
    Cadmium(II) and cobalt(II) coordination polymers constructed from 4,4′-di(1H-imidazol-4-yl)biphenyl and varied multicarboxylate ligands: Synthesis, structure and property
    摘要:
    Five new coordination polymers [Cd-2(H2L)(BPDA)(2)] (1), [Cd-2(HL)(H2L)(1.5)(BHTC)]center dot H2O (2), [Cd-2(H2L)(2) (BPTC)]center dot H2L (3), [CO2(HL)(2)(BPDA)] (4) and [Co-2(H2L)(2)(BPTC)]center dot 4H(2)O (5) have been isolated by reactions of corresponding metal salt with 4,4'-di(1H-imidazol-4-yl)biphenyl (H2L) and multicarboxylic acids of biphenyl-4,4'-dicarboxylic acid (H(2)BPDA), biphenyl-3,4',5-tricarboxylic acid (H3BHTC) and biphenyl-3,3',5,5'-tetracarboxylic acid (H4BPTC) and structurally characterized. 1 forms a 5-fold interpenetrating 3D dmp net by cross-linking of two different kinds of infinite zigzag chains of Cd-H2L and Cd-BPDA, 2 and 5 are 2D networks with different topologies, 3 is a 3D sqc11 net with Cd-BPTC layers pillared by H2L, while 4 exhibits a 3D InS net with Co-H2L 2D networks further connected by BPDA(2-) ligands. Thermal stability of the complexes, solid state luminescent property of 1-3 and sorption property of 5 have been investigated. (C) 2014 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.poly.2014.05.020
点击查看最新优质反应信息

文献信息

  • Structural Diversity and Sensing Properties of Metal–Organic Frameworks with Multicarboxylate and 1<i>H</i>-Imidazol-4-yl-Containing Ligands
    作者:Zhi-Qiang Liu、Kai Chen、Yue Zhao、Yan-Shang Kang、Xiao-Hui Liu、Qing-Yi Lu、Mohammad Azam、Saud I. Al-Resayes、Wei-Yin Sun
    DOI:10.1021/acs.cgd.7b01572
    日期:2018.2.7
    [Cd(L1)(oba)]·DMF (1), [Ni3(L1)2(BPT)2(H2O)4] (2), [Zn2(L1)2(HBPT)2H2O (3), [Ni(L1)(BPTC)0.5(H2O)2] (4), [Ni2(μ2-O)(L2)3(Hoba)2(H2O)2] (5), and [Ni2(L2)3(BPTC)(H2O)2]·6H2O (6) [H2oba = 4,4′-oxybis(benzoic acid), H3BPT = biphenyl-3,4′,5-tricarboxylic acid, H4BPTC = biphenyl-3,3′,5,5′-tetracarboxylic acid, DMF = N,N-dimethylformamide] were achieved and structurally characterized. MOFs 1, 3, 4, and 5
    两个含1 H-咪唑-4-基的配体1,3-二(1 H-咪唑-4-基)苯(L 1)和4,4'-二(1 H-咪唑-4-基)联苯(L 2)用于在热和溶剂热条件下与相应的属盐与各种羧酸配体反应,以及六种新的属有机骨架(MOF)[Cd(L 1)(oBA)]·DMF(1), [Ni 3(L 1)2(BPT)2(H 2 O)4 ](2),[Zn 2(L 1)2(HBPT)2 ]·H2 O(3),[(L 1)(BPTC)0.5(H 2 O)2 ](4),[2(μ 2 -O)(L 2)3(HOBA)2(H 2 O)2 ](5)和[Ni 2(L 2)3(BPTC)(H 2 O)2 ]·6H 2 O(6)[H 2 oBA = 4,4'-氧双(苯甲酸),H 3 BPT =联苯-3,4',5-三羧酸H 4获得了BPTC =联苯-3,3′,5,5′-四羧酸DMF =N,N-二甲基甲酰胺。的MOF 1,3,
  • HEPATITIS C VIRUS INHIBITORS
    申请人:Bristol-Myers Squibb Company
    公开号:EP2513091B1
    公开(公告)日:2017-04-12
  • COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS
    申请人:Bristol-Myers Squibb Company
    公开号:EP3019196B1
    公开(公告)日:2018-06-06
  • [EN] DEUTERATED ANALOGUES OF DACLATASVIR<br/>[FR] ANALOGUES DEUTÉRIÉS DU DACLATASVIR
    申请人:CONCERT PHARMACEUTICALS INC
    公开号:WO2016089814A1
    公开(公告)日:2016-06-09
    This invention relates to novel 4,4'-di(1H-imidazol-5-yl)-1,1'-biphenyl compounds, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NS5A inhibitor.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫